Search Result

Isoforms Recommended:	CLK

Results for "

CLK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (1) Casein Kinase (5) Caspase (1) CDK (24) DYRK (11) GSK-3 (3) Interleukin Related (3) IRAK (3) MDM-2/p53 (1) MELK (2) mTOR (2) PARP (1) Pim (2) Reference Standards (1) RET (3) Ribosomal S6 Kinase (RSK) (2) RIP kinase (2) SGK (1) Small Interfering RNA (siRNA) (4) SRPK (1) STK33 (3) Tau Protein (1) TNF Receptor (3) Wnt (2)
By Research Areas:	Cancer (24) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147141

HS-276 2 Publications Verification	IRAK TNF Receptor Casein Kinase Interleukin Related	Inflammation/Immunology
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 reduces the expression of TNF, IL-6, and IL-1β. HS-276 can be used for rheumatoid arthritis (RA) research .

HY-144875

Rogocekib CTX-712	CDK	Cancer
Rogocekib is an orally effective *CLK 2* inhibitor, with an IC₅₀ of 1.4 nM, showing anti-tumor activity ^[2].

HY-112296

T025 4 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of **Cdc2-like kinase (CLKs)*, with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀* values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .

HY-115470

CLK-IN-T3 3 Publications Verification	CDK DYRK	Cancer
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC₅₀s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity .

HY-132175

CK2 inhibitor 2	Casein Kinase	Cancer
CK2 inhibitor 2 is a potent, selective and orally active inhibitor of *CK2, with an IC₅₀* of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC₅₀=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .

HY-108709

CC-671 1 Publications Verification	CDK	Cancer
CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC₅₀s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

HY-15951

ML167 CID44968231; NCGC00188654	CDK DYRK	Cancer
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .

HY-149262

CLK1-IN-3	CDK DYRK Autophagy	Cancer
CLK1-IN-3 (compound 10ad) is a potent and selective *Clk1* inhibitor, with an IC₅₀ of 5 nM and over 300-fold selectivity for Dyrk1A. CLK1-IN-3 also shows a relatively potent inhibition against *Clk2* and *Clk4, with IC₅₀* values of 42 and 108 nM, respectively. CLK1-IN-3 potently induces autophagy in vitro. CLK1-IN-3 can be used for acute liver injury (ALI) research .

HY-137443

Ipivivint 1 Publications Verification	CDK Wnt	Cancer
Ipivivint (Compound 38) is an orally active and potent CDC-like kinase (CLK) inhibitor with EC₅₀ of 1 nM and 7 nM for CLK2 (human) and CLK3 (human), respectively. Ipivivint also inhibits the Wnt pathway (EC50=13 nM) and tyrosine phosphorylation-regulated kinase 1A (human) (EC₅₀=5 nM) ^[2].

HY-122665

HTH-01-091	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 also inhibits *PIM1/2/3, RIPK2, DYRK3, smMLCK* and *CLK2*. HTH-01-091 can be uesd for breast cancer research .

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively ^[2].

HY-131978

DB18	CDK	Cancer
DB18 is a potent and selective inhibitor of **CDC2-like kinases (CLKs), with IC₅₀** values in the range of 10-30 nM for CLK1, CLK2 and CLK4. DB18 has anti-tumor activity .

HY-123600

SRI-29329 1 Publications Verification	CDK	Others
SRI-29329 is a specific *CLK* inhibitor, with IC₅₀ values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively .

HY-113825

CLK1/2-IN-1	CDK	Cancer
CLK1/2-IN-2 is *CLK1* and *CLK2* inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-P10042

S6K Substrate	Ribosomal S6 Kinase (RSK)	Others
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .

HY-153708

*SGC-CLK-1* CAF-170	CDK	Cancer
SGC-CLK-1, a chemical probe, is a potent and selective inhibitor of **Cdc2-like kinases CLK1, CLK2, and CLK4*. SGC-CLK*-1 can inhibit the growth of melanoma and glioblastoma cells .

HY-125290

MU1210	CDK DYRK	Cancer
MU1210 (compound 12f), a chemical probe, is an inhibitor of CDC-like kinases *Clk1, Clk2, and Clk4* (with IC₅₀ values of 8, 20, and 12 nM respectively), with IC₅₀ for HIPK1 and *DYRK2* are 187 and 1309 nM. MU1210 also has favorable pharmacokinetic characteristics (in mice, 10 mg/kg, intraperitoneal injection: C_max=1.24 μM, T_1/2=58 minutes; no acute toxicity observed) .

HY-RS16769

Clk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk2 Mouse Pre-designed siRNA Set A Clk2 Mouse Pre-designed siRNA Set A

HY-RS02817

CLK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK2 Human Pre-designed siRNA Set A CLK2 Human Pre-designed siRNA Set A

HY-162398

LQ23	CDK	Inflammation/Immunology
LQ23 is a selective inhibitor for CDC2-like kinase 2 (CLK2) with an IC₅₀ of 1.4 nM. LQ23 exhibits anti-inflammatory activity .

HY-113831

CLK1/2-IN-3	CDK SRPK	Cancer
LK1/2-IN-3 (compound 3) is a potent and selective *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .

HY-122665A

HTH-01-091 TFA	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits *PIM1/2/3, RIPK2, DYRK3, smMLCK* and *CLK2*. HTH-01-091 TFA can be uesd for breast cancer research .

HY-125202

KuWal151	CDK DYRK	Cancer
KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines .

HY-RS23209

Clk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk2 Rat Pre-designed siRNA Set A Clk2 Rat Pre-designed siRNA Set A

HY-125201

Indazole 1	CDK	Inflammation/Immunology
Indazole 1 is a potent CDC2-like kinase 2 (CLK2) inhibitor (IC₅₀=12.3 nM). Indazole 1 inhibits the phosphorylation of SR proteins (e.g., SRSF1, SRSF3) and modulates alternative splicing of Wnt signaling-related genes. Indazole 1 is promising for research of osteoarthritis .

HY-173510

CLK2/3-IN-1	CDK	Cancer
CLK2/3-IN-1 (Compound 7c) is an orally active *CLK2/3* inhibitor (EC₅₀: 5.07 nM and 30.03 nM, respectively). CLK2/3-IN-1 binds to Lys193 and Lys186 of CLK2/3 via hydrogen bonds. CLK2/3-IN-1 can inhibit the proliferation of SW480 tumor cells (IC₅₀: 163 nM). CLK2/3-IN-1 can be used to study CLK-related tumor diseases .

HY-P10042A

S6K Substrate acetate	Ribosomal S6 Kinase (RSK)	Others
S6K Substrate acetate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .

HY-176885

CDD-2211	STK33 RET	Others
CDD-2211 is a STK33 inhibitor, with a K_d of 0.018 nM and an IC₅₀ of 5 nM. CDD-2211 has relatively weak inhibitory effects on off-target kinases, with IC₅₀ values of 115 nM for *CLK1, 48 nM for CLK2, 187 nM for CLK4, and 78 nM for RET*. CDD-2211 can be used for the study of contraception .

HY-176885A

CDD-2212	STK33 RET	Others
CDD-2212 is a STK33 inhibitor, with a K_d of 1.9 nM and an IC₅₀ of 999 nM. CDD-2212 has relatively weak inhibitory effects on off-target kinases, with IC₅₀ values of 3223 nM for *CLK1, 1555 nM for CLK2, 5884 nM for CLK4, and 1093 nM for RET*. CDD-2212 can be used for the study of contraception .

HY-168209

LBM22	Wnt CDK Apoptosis	Cancer
LBM22 is a **CDC2-like kinase 2 (CLK2) inhibitor with the IC₅₀** of 3.9 nM. LBM22 has antiproliferative activity and inhibits serine/arginine-rich (SR) protein phosphorylation. LBM22 down-regulates the expression of Wnt-related proteins and anti-apoptotic proteins and can be used for study of non-small cell lung cancer .

HY-123853

CAM4066	Casein Kinase	Cancer
CAM4066 is a potent *CK2α* inhibitor, with an IC₅₀ value of 300 nM. CAM4066 exhibits high selectivity, with IC₅₀ values of 22.35, 43.55, and > 50 μM for HIPK3, DAPK3, and CLK2, respectively. CAM4066 shows no cell activity. CAM4066 can be used for the development of highly potent CK2 inhibitors .

HY-113670

CLK1/2-IN-2	CDK	Cancer
CLK1/2-IN-2 is *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-176884

CDD-2110	STK33 RET	Others
CDD-2210 is a STK33 inhibitor, with a K_d of 0.1 nM and an IC₅₀ of 38 nM. CDD-2210 has relatively weak inhibitory effects on off-target kinases, with IC₅₀ values of 1209 nM for *CLK1, 917 nM for CLK2, 544 nM for CLK4, and 746 nM for RET*. CDD-2210 can be used for the study of contraception .

HY-157995

Dyrk1A-IN-7	DYRK	Metabolic Disease Inflammation/Immunology Cancer
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC₅₀ value of DYRK1A is 28 nM. For CLK2, K_d is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .

HY-108709R

CC-671 (Standard)	Reference Standards CDK	Cancer
CC-671 (Standard) is the analytical standard of CC-671 (HY-108709). This product is intended for research and analytical applications. CC-671 is a dual TTK protein K_inase/CDC2-like K_inase (CLK2) inhibitor with IC₅₀s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

HY-RS14360

TELO2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TELO2 Human Pre-designed siRNA Set A contains three designed siRNAs for TELO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TELO2 Human Pre-designed siRNA Set A TELO2 Human Pre-designed siRNA Set A

HY-183831

GPS167	MDM-2/p53 PARP Caspase Apoptosis	Cancer
GPS167 is a *CLK* kinase inhibitor that potently and selectively inhibits recombinant human *CLK1, CLK2* and *CLK4. By inhibiting CLK-mediated phosphorylation of SRSF10, GPS167 upregulates the protein-binding ability of CLK1 and CLK4 with SRSF10, downregulates oncogenic BCLAF1-L* and upregulates tumor-suppressive BCLAF1-S, regulates alternative splicing of genes such as *MDM2* and MDM4, stabilizes p53 protein and induces DNA damage, ultimately triggering tumor cell apoptosis. GPS167 can block the epithelial-mesenchymal transition process of tumors, activate intracellular double-stranded RNA-mediated antiviral immune responses, and produce synergistic cytotoxicity when combined with microtubule-targeting drugs. GPS167 can be used in research related to various cancers including colorectal cancer ^[2] .

HY-147141A

HS-276 hydrochloride	IRAK TNF Receptor Casein Kinase Interleukin Related	Inflammation/Immunology
HS-276 hydrochloride is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 hydrochloride shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 hydrochloride reduces the expression of TNF, IL-6, and IL-1β. HS-276 hydrochloride can be used for rheumatoid arthritis (RA) research .

HY-147141B

HS-276 formic	IRAK TNF Receptor Casein Kinase Interleukin Related	Inflammation/Immunology
HS-276 formic is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 formic shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 formic reduces the expression of TNF, IL-6, and IL-1β. HS-276 formic can be used for rheumatoid arthritis (RA) research .

HY-182323

SGK1-IN-7	SGK Tau Protein	Neurological Disease
SGK1-IN-7 is a blood-brain barrier-permeable SGK1 inhibitor with an IC₅₀ of 0.72 μM. SGK1-IN-7 reduces the phosphorylation level of TAU protein at the Ser396 and Ser214 epitopes. SGK1-IN-7 antagonizes the toxicity induced by Okadaic acid (HY-N6785). SGK1-IN-7 can be used in the research of Alzheimer's disease .

S6K Substrate	Ribosomal S6 Kinase (RSK)	Others
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .

S6K Substrate acetate	Ribosomal S6 Kinase (RSK)	Others
S6K Substrate acetate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .

Recombinant Proteins Recommended:

CLK2

Species:	Human (2)
Tag:	His (1) GST (2)
Source:	sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701664

	CLK2 Protein, Human (Active, GST) CLK2; Dual specificity protein kinase CLK2; CDC-like kinase 2	Human	E. coli
	The CLK2 protein is a dual-specificity kinase that phosphorylates serine- and arginine-rich (SR) proteins in the spliceosome complex. CLK2 Protein, Human (GST) is the recombinant human-derived CLK2 protein, expressed by E. coli , with N-GST labeled tag.

HY-P705762

	CLK2 Protein, Human (Active, sf9, His-GST) CLK2; Dual specificity protein kinase CLK2; CDC-like kinase 2	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: